Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Moorenstr. 5, Düsseldorf 40225, Germany.
Hematol Oncol Clin North Am. 2020 Apr;34(2):465-473. doi: 10.1016/j.hoc.2019.10.006. Epub 2020 Jan 21.
Iron overload (IOL) in patients with myelodysplastic syndromes (MDS) is mainly attributable to chronic transfusion therapy. The importance of iron chelation therapy (ICT) in MDS has been a matter of debate. The Telesto study, the only randomized, placebo-controlled trial of ICT with deferasirox in MDS, showed improved event-free survival with ICT in patients with lower-risk MDS. Although Telesto was not powered to detect differences between deferasirox and placebo for single-event categories of the composite primary endpoint for event-free survival, results are consistent with the view that iron-related cardiac dysfunction is ameliorated by ICT in elderly patients with MDS.
骨髓增生异常综合征（MDS）患者的铁过载（IOL）主要归因于慢性输血治疗。铁螯合疗法（ICT）在 MDS 中的重要性一直存在争议。Telesto 研究是唯一一项针对 MDS 用地拉罗司进行 ICT 的随机、安慰剂对照试验，结果表明 ICT 可改善低危 MDS 患者的无事件生存。尽管 Telesto 没有足够的效力来检测地拉罗司与安慰剂在无事件生存的复合主要终点的单一事件类别之间的差异，但结果与以下观点一致，即 ICT 可改善 MDS 老年患者的铁相关心脏功能障碍。
